S
Shengyuan Yu
Researcher at Chinese PLA General Hospital
Publications - 250
Citations - 3578
Shengyuan Yu is an academic researcher from Chinese PLA General Hospital. The author has contributed to research in topics: Migraine & Medicine. The author has an hindex of 24, co-authored 198 publications receiving 2346 citations. Previous affiliations of Shengyuan Yu include Chinese General Hospital College of Nursing and Liberal Arts.
Papers
More filters
Journal ArticleDOI
A clinical study of miliary brain tuberculomas in China
Ming Yang,Jia-tang Zhang,Yan Yao,Qing-Che Tan,Ting Gao,Chenglin Tian,Xusheng Huang,Shengyuan Yu +7 more
TL;DR: All patients began to recover within 2 weeks of initiating antitubercular therapy (ATT), the number of lesions visible on MRI scans was halved within a month, and all lesions had healed without sequelae after 18 months of regular ATT.
Journal ArticleDOI
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Duliang Soft Capsule in Patients with Chronic Daily Headache
Shengyuan Yu,Yueqing Hu,Qi Wan,Jiying Zhou,Xinfeng Liu,Xiangyang Qiao,Xiaosu Yang,Jiachun Feng,Kangning Chen,Xiaoping Pan,Qingwu Yang,Linsen Dou,Ming Liu,Yangmei Chen,Tingmin Yu,Juming Yu,Zhiwei Li,Xue Bai,Jingfeng Duan +18 more
TL;DR: DSC might be an effective and well-tolerated option for the prophylactic treatment of patients with CDH and no statistical difference was found between the two groups in the associated symptoms.
Journal ArticleDOI
Gender differences among Chinese patients with neuromyelitis optica spectrum disorders.
TL;DR: Women with NMOSD have higher morbidity levels than men with this disease and are more likely to have autoimmune diseases and brainstem lesions, especially in the area postrema.
Journal ArticleDOI
Evaluation of the efficacy and safety of vilazodone for treating major depressive disorder.
TL;DR: The findings indicate that the novel antidepressant vilazodone is effective and safe for MDD, with a low occurrence of side effects, and offers promise as an effective oral drug for the treatment of MDD.
Journal ArticleDOI
Association between angiotensin-converting enzyme insertion/deletion polymorphism and migraine: a meta-analysis.
TL;DR: The data suggest that the ACE II genotype could exert a protective effect against migraine with aura and without aura at least in the Turkish population.